ArriVent BioPharma Inc
NASDAQ:AVBP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
ArriVent BioPharma Inc
NASDAQ:AVBP
|
US |
|
Cizzle Biotechnology Holdings PLC
F:E7F0
|
UK |
|
Cedar Fair LP
NYSE:FUN
|
US |
|
Ryanair Holdings PLC
F:RY4D
|
IE |
|
K
|
Karnov Group AB (publ)
F:3UA
|
SE |
|
International Petroleum Corp
OTC:IPCFF
|
CA |
|
F
|
Flight Centre Travel Group Ltd
OTC:FGETF
|
AU |
|
Hims & Hers Health Inc
BMV:HIMS
|
US |
|
P
|
Pultegroup Inc
DUS:PU7
|
US |
|
V
|
Vidrala SA
SWB:VIR
|
ES |
|
Q
|
Quanta Services Inc
F:QAA
|
US |
Intrinsic Value
Is AVBP undervalued or overvalued?
See the intrinsic value estimate for ArriVent BioPharma Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
AVBP looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with AVBP’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What ArriVent BioPharma Does
ArriVent Biopharma is a clinical-stage drug company focused on cancer medicines. It does not sell a broad line of products; instead, it develops targeted therapies for patients whose tumors are driven by specific genetic changes. Its main asset is an EGFR-targeted drug program, and its work centers on testing, advancing, and licensing cancer treatments that can become prescription medicines if they succeed in trials and win approval.
- Headquarters
- United States of America US
- Employees
- 77
- IPO date
- Jan 26, 2024
Earnings Waterfall
ArriVent BioPharma Inc
The intrinsic value for ArriVent BioPharma Inc (AVBP) under the Base Case is hidden USD.
Compared with the current market price of 15.3 USD, the stock appears hidden.